The AI Reckoning — Episode 4: Who Wins

Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠#pharma, #AI strategy, #competitive advantage, #China pharma, #cross-border licensing, #FDA, #EMA, #NMPA, #regulatory divergence, #Eli Lilly, #Recursion, #GSK, #build vs buy